{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:18:38Z","timestamp":1782602318037,"version":"3.54.5"},"reference-count":13,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To report a case of propofol-induced priapism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Summary:<\/jats:title>\n                    <jats:p>A 17-year-old male receiving propofol for induction of anesthesia during a cardiac ablation procedure developed priapism that required medical intervention and discontinuation of propofol. The priapism developed after a total propofol dose of 550 mg, lasted for 2 hours, and resolved immediately following medical intervention. The following day, the patient underwent a transesophageal echocardiogram and received a total propofol dose of 40 mg throughout the procedure. He again developed priapism, which resolved within one hour without medical intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Priapism experienced by this patient is considered to be drug-induced because of the temporal relationship, recurrence with rechallenge, and dose\u2013response relationship. Using the Naranjo probability scale, we determined that propofol was a highly probable causative agent of priapism in this patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Although, as of April 4, 2006, this adverse effect has not been previously reported, there is a strong correlation of propofol to priapism in this patient. Clinicians should be aware of this adverse effect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1g555","type":"journal-article","created":{"date-parts":[[2006,4,26]],"date-time":"2006-04-26T00:06:41Z","timestamp":1146010001000},"page":"980-982","source":"Crossref","is-referenced-by-count":26,"title":["Propofol-Induced Priapism, a Case Confirmed with Rechallenge"],"prefix":"10.1177","volume":"40","author":[{"given":"Kimi S","family":"Vesta","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma, Oklahoma City, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaunta' D","family":"Martina","sequence":"additional","affiliation":[{"name":"Internal Medicine Pharmacy Practice Resident, Department of Pharmacy, Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen A","family":"Kozlowski","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, OU Medical Center, Oklahoma City"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2006,5,1]]},"reference":[{"key":"bibr1-aph.1G555","volume-title":"Package insert. Diprivan (propofol)","year":"2004"},{"key":"bibr2-aph.1G555","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcl.2004.01.008"},{"key":"bibr3-aph.1G555","doi-asserted-by":"publisher","DOI":"10.4065\/72.4.350"},{"key":"bibr4-aph.1G555","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1986.tb09008.x"},{"key":"bibr5-aph.1G555","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)52106-0"},{"key":"bibr6-aph.1G555","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr7-aph.1G555","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2044.2003.03147.x"},{"key":"bibr8-aph.1G555","doi-asserted-by":"publisher","DOI":"10.1177\/0148607192016002171"},{"key":"bibr9-aph.1G555","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1987.tb04812.x"},{"key":"bibr10-aph.1G555","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)49257-3"},{"key":"bibr11-aph.1G555","doi-asserted-by":"publisher","DOI":"10.1007\/BF02938196"},{"key":"bibr12-aph.1G555","doi-asserted-by":"publisher","DOI":"10.1177\/003693307902400214"},{"key":"bibr13-aph.1G555","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/54.6.694"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1G555","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1G555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:42Z","timestamp":1777374462000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1G555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["10.1345\/aph.1G555"],"URL":"https:\/\/doi.org\/10.1345\/aph.1g555","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}